58 related articles for article (PubMed ID: 36892260)
1. Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Liu Y; Pan J; Gao F; Xu W; Li H; Qi X
Adv Ther; 2023 Feb; 40(2):521-549. PubMed ID: 36399316
[TBL] [Abstract][Full Text] [Related]
2. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.
Wang H; Hu L; Zhang F; Fang M; Xu J; Li M; Chen Z
Oral Oncol; 2024 Jun; 153():106814. PubMed ID: 38714115
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Programmed Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Checkpoint Inhibitors in Patients With Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.
Hong X; Zhang Y; Chi Z; Xu Q; Lin W; Huang Y; Lin T; Zhang Y
Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):e20-e30. PubMed ID: 37993317
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
Anand K; Sahu G; Burns E; Ensor A; Ensor J; Pingali SR; Subbiah V; Iyer SP
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817069
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A meta-analysis and systematic review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; ():. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M; Chen L; Godfrey J; Song J; Egelston C; Puverel S; Budde LE; Armenian S; Nikolaenko L; Nwangwu M; Guo W; Gao L; Lee P; Chen R; Daniels S; Kennedy N; Peters L; Zain J; Rosen S; Forman S; Popplewell L; Kwak L; Herrera AF
Blood; 2023 Oct; 142(16):1359-1370. PubMed ID: 37339586
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of PD-1/PD-L1 inhibitors monotherapy in patients with endometrial cancer.
Wan X; Huang J; Huang L; Wang Y; Fu Y; Jin X; Huang Z; Xiong J
Discov Oncol; 2024 May; 15(1):168. PubMed ID: 38750182
[TBL] [Abstract][Full Text] [Related]
10. STAT3 Expression and Its Correlation with PD-L1 Expression in Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population.
Hambalie AO; Norahmawati E; Endharti AT; Retnani DP; Rahmadiani N
Adv Hematol; 2024; 2024():7989996. PubMed ID: 38817669
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.
Zhang Y; Ye J; Chen H; Zhou D; Ji C
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473226
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of Hodgkin lymphoma: Current and future approaches.
Ullah F; Dima D; Omar N; Ogbue O; Ahmed S
Front Oncol; 2023; 13():1067289. PubMed ID: 36937412
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors affecting immune checkpoint inhibitor therapy in tumor patients exposed to antibiotics.
Chen Q; Zhang Z; Li X; Feng S; Liu S
Front Oncol; 2023; 13():1204248. PubMed ID: 37483503
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.
Marjańska A; Pawińska-Wąsikowska K; Wieczorek A; Drogosiewicz M; Dembowska-Bagińska B; Bobeff K; Młynarski W; Adamczewska-Wawrzynowicz K; Wachowiak J; Krawczyk MA; Irga-Jaworska N; Węcławek-Tompol J; Kałwak K; Sawicka-Żukowska M; Krawczuk-Rybak M; Raciborska A; Mizia-Malarz A; Sobocińska-Mirska A; Łaguna P; Balwierz W; Styczyński J
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473329
[TBL] [Abstract][Full Text] [Related]
17. Suspected NUT carcinoma progressing on pembrolizumab, carboplatin, and paclitaxel as first-line treatment: a case report.
Badran A; Ali SS; Arabi TZ; Alaklabi AM; Abdalla HM; Mohammed S; Sabbah BN; Elshenawy MA; Atallah JP
Ann Med Surg (Lond); 2024 Feb; 86(2):1061-1065. PubMed ID: 38333300
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibition in hematologic malignancies.
Tsumura A; Levis D; Tuscano JM
Front Oncol; 2023; 13():1288172. PubMed ID: 37920162
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
Sun C; Chen H; Wang Y; Zheng C
Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
